The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) scheduled a conference to discuss Janssen Biotech Inc.’s request for emergency use authorization (EUA) for its COVID-19 vaccine. The VRBPAC is scheduled to meet on February 26, 2021, which means the FDA will have time “to thoroughly evaluate the data and information submitted in the EUA request before the meeting.” To ensure that advisory committee members engage in a robust public discussion, the FDA plans to issue a detailed Federal Register notice, accept comments from the public, and livestream the VRBPAC meeting on social media platforms.
Click here for more details.
(Source: FDA Announcement - February 4, 2021)
Click here for our COVID-19 vaccines updates.